Baseline clinical characteristics | CD Spanish cohort (n=34) | CD Belgian cohort (n=53) | Comparison between cohorts (p value) |
---|---|---|---|
Male/female (%) | 13/21 (38.2/61.7) | 28/25 (52.8/47.2) | 0.201 |
Median (IQR) age at surgery (years) or at sample collection | 34 (18 –58) | 41.3 (26.5–52.9) | 0.141 |
Median duration of disease (IQR) at surgery (years) or at sampling | 6.5 (0–28) | 15.7 (4.1–27.1) | 0.0002 |
Maximum disease location (Montreal classification) | 0.682 | ||
L1 ileal (%) | 12 (35) | 18 (34) | |
L2 colonic (%) | 0 (0) | 0 (0) | |
L3 ileocolonic (%) | 22 (64.7) | 35 (66) | |
L4 isolated upper disease (%) | 2 (5.8) | 2 (3.8) | |
Disease behaviour at surgery (Montreal classification) | 0.009 | ||
B1 non-stricturing, non-penetrating (%) | 3 (8.8) | 2 (3.8) | |
B2 stricturing (%) | 22 (64.7) | 21 (39.6) | |
B3 penetrating (%) | 5 (14.7) | 30 (56.6) | |
p perianal disease (%) | 3 (8.8) | 15 (28.3) | |
Active smoking at surgery (%) | 10 (29.4) | 16 (30.2) | 0.012 |
Medication at surgery or at sampling | |||
Mesalamine–sulfasalazine (%) | 4 (11.8) | 4 (7.5) | 0.012 |
Corticosteroids (%) | 2 (2.9) | 10 (18.9) | 0.183 |
Immunosuppressants (%) | 14 (41.1) | 12 (22.6) | 0.087 |
Anti-TNF (%) | 12 (23.5) | 7 (13.2) | 0.023 |
Antibiotics (%) | 0 (0) | 9 (16.9) | 0.033 |
Methotrexate | 1 (2.9) | ||
Other | 10 (29.4) | ||
None | 1 (2.9) | ||
UC Spanish cohort 1 (n=33) | UC Spanish cohort 2 (n=41) | ||
Male/female (%) | 9/24 (27.2/72.7) | 17/24 (41.4/58.5) | 0.595 |
Median (IQR) age at sample collection | 43 (24–62) | 43 (24–68) | 0.500 |
Median duration of disease (IQR) at sampling | 9 (1–23) | 10 (1–34) | 0.392 |
Disease behaviour at sampling | 0.208 | ||
E1 proctitis | 9 (27.3) | 18 (43.9) | |
E2 left sided colitis | 11 (33.3) | 10 (24.4) | |
E3 pancolitis | 13 (39.4) | 13 (31.7) | |
Medication at sampling | |||
Mesalamine (%) | 11 (24) | 26 (63.4) | 0.021 |
Corticosteroids (%) | 2 (6) | 0 | 0.617 |
Immunosuppressants (%) | 8 (24) | 0 | 0.026 |
Other | 2 (6) | 3 (7.3) | 0.708 |
None | 2 (4.8) |
Comparison between cohorts have been performed; the χ2 test was applied to categorical variables, and the t-test was applied to continuous variables; when p<0.05 differences were considered significant.
CD, Crohn's disease; TNF, tumour necrosis factor.